Eli Lilly and Company (NYSE: LLY) announced new first‑line data on olomorasib, its investigational next‑generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain – showing median progression‑free survival (PFS) and duration of response (DOR) not reached after nearly 21 months of median follow‑up in first‑line KRAS G12C‑mutant non‑small cell lung cancer (NSCLC).
Presentation Snapshot
| Item | Detail |
|---|---|
| Company | Eli Lilly and Company (NYSE: LLY) |
| Asset | Olomorasib – investigational next‑generation KRAS G12C inhibitor |
| Congress | ESMO 2026, Madrid, Spain |
| Presentation Date | 25 October 2026 |
| Setting | First‑line KRAS G12C‑mutant advanced NSCLC |
| Studies | Phase 1/2 LOXO‑RAS‑20001; safety lead‑in of Phase 3 SUNRAY‑01 |
| Key Partners/Combination | Merck’s anti‑PD‑1 therapy KEYTRUDA® (pembrolizumab), with and without chemotherapy |
Drug Profile & Mechanism of Action
- Molecule: Olomorasib, a potent, selective, next‑generation oral KRAS G12C inhibitor specifically intended to target the mutation.
- Mechanism: Binds the mutated KRAS G12C protein and locks it in its inactive state, blocking oncogenic signaling.
- Differentiating Properties: Designed for high predicted target occupancy and potency, potentially allowing safer, flexible combination with standard‑of‑care immunotherapy – with or without chemotherapy.
- Combination Strategy: Being evaluated alongside pembrolizumab (KEYTRUDA®) monotherapy and full chemoimmunotherapy (pembrolizumab + pemetrexed + platinum) regimens in the first‑line setting.
Clinical Evidence – First‑Line KRAS G12C‑Mutant NSCLC
| Endpoint | Regimen | Result | Follow‑Up |
|---|---|---|---|
| Median PFS | Olomorasib + pembrolizumab (no chemo) | Not reached | Median ~21 months |
| Median DOR | Olomorasib + pembrolizumab (no chemo) | Not reached | Median ~21 months |
| Activity by PD‑L1 | Olomorasib + pembrolizumab (no chemo) | Durable activity observed across PD‑L1 levels | – |
| ORR (investigator‑assessed) | Olomorasib + chemoimmunotherapy (pembrolizumab, pemetrexed, platinum) | 62 % | Median ~19 months |
| Median DOR | Olomorasib + chemoimmunotherapy | 14.5 months | Median ~19 months |
The no‑chemotherapy data came from a poster presentation covering the Phase 1/2 LOXO‑RAS‑20001 trial and the safety lead‑in portion of the Phase 3 SUNRAY‑01 trial; the chemoimmunotherapy results (ORR 62 %, median DOR 14.5 months) were delivered in a separate rapid oral presentation at the congress.
Market Impact & Outlook
- First‑Line Ambition: By moving KRAS G12C inhibition into the first‑line setting, olomorasib targets the largest segment of the KRAS G12C‑mutant NSCLC population – a substantially bigger commercial opportunity than previously approved later‑line inhibitors.
- Chemo‑Free Potential: Median PFS and DOR not reached at nearly 21 months for the chemotherapy‑free pembrolizumab combination suggests a potential de‑escalation pathway, sparing patients platinum chemotherapy toxicity if confirmed in the ongoing Phase 3 SUNRAY‑01.
- PD‑L1 Agnostic Activity: Durable responses across PD‑L1 levels broaden the addressable patient population beyond biomarker‑selected subgroups, strengthening olomorasib’s positioning against PD‑L1–dependent immunotherapy strategies.
- Competitive Landscape: As a next‑generation inhibitor with high predicted target occupancy designed for safer combinations, olomorasib is positioned to compete against first‑generation KRAS G12C agents and emerging pan‑KRAS programs in the crowded RAS‑targeted oncology field.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding olomorasib, including ongoing clinical development (SUNRAY‑01), regulatory submissions and timelines, safety and efficacy outcomes, and commercial potential. Olomorasib remains investigational and has not been approved by any regulatory authority for any indication; actual results may differ materially due to trial outcomes, regulatory review, competitive dynamics, and other risks.-Fineline Info & Tech
